GlobalData on MSN
Dizal’s phase III NSCLC trial of Zegfrovy meets primary endpoint
The open-label trial enrolled patients across 16 countries and regions in Europe, Asia, South America, and North America.
Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell ...
Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di ...
In 2006, Diana Lindsay, who had never so much as held a cigarette, was diagnosed with stage 4 lung cancer. It had metastasized to both lungs, her brain and lymph nodes. Keith Eaton, MD, PhD, clinical ...
This schematic illustration depicts the intricate EGF/EGFR signaling pathways in oral keratinocytes. Under specific culture conditions, activating the EGFR/Src/PI3K/Akt/mTOR pathway enhances cell ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS ...
The acquisition aims to accelerate the development of targeted therapies for EGFR mutant NSCLC patients globally.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results